Company news

Share this content:
Astellas Pharma Technologies is offering early retirement to 200 workers at its Norman, OK, plant. The cuts anticipate the patent expiration Flomax.
Merck KGaA, the German manufacturer of Erbitux cancer treatment, has announced a partnership with Belgian biotech Ablynx NV to develop tumor and immune disorder treatments. 
Concentric Pharma Advertising has won an AOR assignment on Surfaxin, an investigational respiratory distress syndrome (RDS) treatment manufactured by Discovery Labs.
Share this content:
Scroll down to see the next article